Arvee Laboratories (India) Ltd. AI Stock Analysis
Want to see IN:ARVEE full AI Analyst Report?
Arvee Laboratories (India) Ltd. (ARVEE) AI Stock Analysis
Arvee Laboratories (India) Ltd.
(NSE:ARVEE)
The stock's strong technical momentum and robust balance sheet are offset by a very high valuation and weak cash flow generation. While the upward price trend and low debt are significant positives, the negative operating cash flow and expensive P/E ratio present considerable risks.
Arvee Laboratories (India) Ltd. (ARVEE) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 2.45B
- Dividend Yield
- ―
- Average Volume (3M)
- 15.96K
- Price to Earnings (P/E)
- 37.1
- Beta (1Y)
- 1.36
- Revenue Growth
- 138.64%
- EPS Growth
- 1536.16%
- Country
- India
- Employees
- 57
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Arvee Laboratories (India) Ltd. Business Overview & Revenue Model
Company Description
Arvee Laboratories (India) Ltd., established in 2012 and headquartered in Ahmedabad, India, specializes in the production and distribution of various specialized chemicals throughout the country. The company's product line includes a range of polymer...
Arvee Laboratories (India) Ltd. Financial Statement Overview
Summary
Mixed financials: Strong balance sheet (Score 88) with minimal debt, but weakened by poor cash flow (Score 40) and moderate income performance (Score 62) due to revenue decline despite margin improvement.
Income Statement
62PositiveBalance Sheet
88Very PositiveCash Flow
40Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 627.37M | 315.14M | 384.87M | 303.42M | 612.76M | 471.44M |
| Gross Profit | 183.33M | 111.68M | 121.63M | 41.49M | 173.09M | 142.99M |
| EBITDA | 86.53M | 31.98M | 42.69M | 30.46M | 86.34M | 61.30M |
| Net Income | 65.97M | 25.26M | 21.47M | 10.52M | 41.19M | 26.77M |
Balance Sheet | ||||||
| Total Assets | 611.88M | 432.57M | 381.58M | 381.99M | 386.85M | 410.46M |
| Cash, Cash Equivalents and Short-Term Investments | 129.31M | 32.82M | 49.06M | 18.65M | 8.92M | 86.39M |
| Total Debt | 10.00M | 11.13M | 10.33M | 10.00M | 10.00M | 88.79M |
| Total Liabilities | 231.50M | 95.30M | 68.97M | 90.85M | 106.23M | 196.08M |
| Stockholders Equity | 380.38M | 337.88M | 312.61M | 291.14M | 280.62M | 214.38M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -29.02M | -17.35M | 10.78M | 14.45M | -5.80M |
| Operating Cash Flow | 0 | -694.00K | 1.19M | 36.64M | 29.29M | 17.11M |
| Investing Cash Flow | 0 | 2.17M | -17.91M | -21.63M | -12.58M | -6.04M |
| Financing Cash Flow | 0 | 802.00K | 333.00K | -1.88M | -24.17M | 45.20M |
Arvee Laboratories (India) Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ARVEE, the sentiment is Positive. The current price of 222.00 is above the 20-day moving average (MA) of 209.12, above the 50-day MA of 203.41, and above the 200-day MA of 171.15, indicating a bullish trend. The MACD of 6.58 indicates Negative momentum. The RSI at 56.99 is Neutral, neither overbought nor oversold. The STOCH value of 64.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ARVEE.
Arvee Laboratories (India) Ltd. Peers Comparison
Overall Rating
IN:TAINWALCHM64Neutral
IN:ARVEE63Neutral
IN:PODDARMENT57Neutral
IN:VINEETLAB47Neutral
IN:SRD46Neutral
IN:AKSHARCHEM41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 64Neutral | INR 1.81B | 23.73 | ― | 1.53% | -17.16% | 3.36% | |
| 63Neutral | INR 2.45B | 37.06 | ― | ― | 138.64% | 1536.16% | |
| 57Neutral | INR 2.71B | 18.18 | ― | 1.57% | 4.50% | -17.13% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 47Neutral | INR 729.65M | 14.98 | ― | ― | 6.45% | ― | |
| 46Neutral | INR 2.99B | 16.18 | ― | 0.11% | 19.82% | 92.88% | |
| 41Neutral | INR 2.84B | 10.00 | ― | 0.14% | 32.59% | 1397.90% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ARVEE | Arvee Laboratories (India) Ltd. | 222.00 | 54.43 | 32.48% | |
| IN:AKSHARCHEM | AksharChem India Ltd. | 353.25 | 98.21 | 38.51% | |
| IN:PODDARMENT | Poddar Pigments Limited | 255.60 | -4.09 | -1.58% | |
| IN:SRD | Shankar Lal Rampal Dye-Chem Ltd. | 46.73 | -23.51 | -33.47% | |
| IN:TAINWALCHM | Tainwala Chemicals & Plastics (India) Ltd | 193.00 | -0.43 | -0.22% | |
| IN:VINEETLAB | Vineet Laboratories Ltd. | 37.99 | 2.45 | 6.89% |
Arvee Laboratories (India) Ltd. Corporate Events
Arvee Laboratories Fined by NSE for Technical SEBI Compliance Lapse
Arvee Laboratories (India) Ltd. operates in the chemicals and laboratory products sector from its base in Ahmedabad and is listed on the National Stock Exchange under the symbol ARVEE. The company functions within SEBI’s stringent listing and disclos...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 29, 2026
